Abbott Laboratories, US0028241000

Abbott Laboratories stock slips to EUR 97.48, down 1.24% premarket

Published on 11/17/2026 at 08:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott narrowed its 2026 comparable sales-growth outlook after reporting third-quarter sales of USD 13.01 billion. On Xetra, the stock closed at EUR 98.70 on Monday, November 16, 2026.

Abbott outlook narrows after third quarter

  • Third-quarter sales rose 14.5 percent year over year to USD 13.01 billion.
  • Abbott narrowed its 2026 comparable sales-growth outlook to about 6 percent while maintaining its adjusted EPS guidance midpoint.
  • The planned Nutrition separation remains targeted for completion by the end of 2027.
Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories stock slipped before Tuesday's European session after the healthcare company narrowed its 2026 comparable sales-growth outlook while maintaining the midpoint of its adjusted earnings guidance.

Abbott reported third-quarter sales of USD 13.01 billion on November 13, up 14.5 percent from a year earlier, according to Stockrow, which summarized the results from Zacks. Adjusted earnings per share rose 9.2 percent to USD 1.42 but missed consensus, while growth extended across pharmaceuticals, medical devices, diagnostics and nutrition.

Abbott stock traded at 97.48 euros on Lang & Schwarz at 08:46 CET on Tuesday, November 17, 1.24 percent below the Xetra close of Monday, November 16, at 98.70 euros.

Guidance and portfolio shifts shape sentiment

The company now expects comparable sales growth of about 6 percent in 2026, compared with its previous 6.5 to 7.5 percent range. Adjusted EPS guidance remains at USD 5.50 to USD 5.55. The outlook reflects pressure in heart devices and slower growth in parts of the nutrition business, while electrophysiology products such as the Volt pulsed-field ablation catheter are supporting the medical-devices portfolio.

Abbott also plans to separate its global Nutrition business into a standalone public company by the end of 2027. For investors, the combination of a tighter sales outlook and continued product expansion leaves execution in cardiology and the separation process as central factors for the remaining year.

Broader healthcare sentiment can be followed through the S&P 500.

More news and analyses on Abbott Laboratories stock.

Disclaimer...
en | US0028241000 | ABBOTT LABORATORIES | boerse | 70525474 | bgmi